TerrAscendTSNDF -6.44%32 Forward PE Ratio is 0.00 as of Jul. 06, 2026. GuruFocus rates TSNDF with a GF Score™ of 32/100 and a GF Value™ of $0.99 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 408 Drug Manufacturers companies, TerrAscend ranks worse than 245097.79% on this metric.
TerrAscend (OTCPK:TSNDF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
TerrAscend Forward PE Ratio Related Terms
TerrAscend Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for TerrAscend's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TerrAscend Forward PE Ratio Chart
TerrAscend Annual Data
Trend
2021-12
Forward PE Ratio
27.78
TerrAscend Quarterly Data
2021-03
2021-06
2021-09
2021-12
2022-03
2022-09
Forward PE Ratio
62.89
88.50
21.41
27.78
416.67
26.25
TSNDF vs ZTS, UTHR: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TerrAscend's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TerrAscend Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TerrAscend's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where TerrAscend's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
TerrAscend (TSNDF) has a Forward PE Ratio of 0.00 as of Jul. 06, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on TerrAscend and its competitors. According to the industry distribution chart, TerrAscend ranks #999999 out of 408 companies in the Drug Manufacturers industry.
Is TerrAscend's Forward PE Ratio too high?
TerrAscend's current Forward PE Ratio is 0.00. Based on the distribution chart, TerrAscend ranks #999999 out of 408 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, TerrAscend has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TerrAscend's Forward PE Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, TerrAscend ranks #999999 out of 408 companies for Forward PE Ratio. This places TerrAscend in the lower half of its industry. The industry median Forward PE Ratio is 17.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.53, based on 408 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on TerrAscend and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TerrAscend's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TerrAscend stock overvalued right now?
Based on GuruFocus' analysis, TerrAscend (TSNDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.99, compared to a current price of $0.59 — trading 40.5% below its estimated fair value. The current Forward PE Ratio is 0.00. TerrAscend's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For TerrAscend (TSNDF), the current Forward PE Ratio is 0.00 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TerrAscend (TSNDF) Overvalued in 2026?
Based on GuruFocus' analysis, TerrAscend stock appears to be undervalued.
The current stock price of $0.59 is trading 40.5% below its estimated GF Value™ of $0.99.
GuruFocus considers TerrAscend to be Possible Value Trap.
Key valuation signals for TSNDF:
Forward PE Ratio: 0.00
GF Value™: $0.99 vs. price of $0.59 (40.5% below fair value)
No single metric tells the full story. See the TSNDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TerrAscend Corp is a company focused on creating and delivering cannabis products and services that meet the evolving needs of its patients. It also provides education and support programs to physicians and patients through healthcare professionals. In addition, the firm operates in California, Maryland, New Jersey, and Pennsylvania, with retail operations in Ohio and Canada. It operates The Apothecarium and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. The firm has one operating segment, being the cultivation, production, and sale of cannabis products, with subsidiaries located in Canada and the United States. The company generates key revenue from the United States.
32GF Score
Get the complete analysis for TSNDF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSNDF has been successfully added to your 